At the recent Celebration of Native Mass Spectrometry in Oxford, we caught up with Michal Sharon to talk about her research and the fascinating evolutionary history of the 20S proteasome. Would you ...

Proteasome inhibitors have brought major advances in the treatment of multiple myeloma (MM), but eventual drug resistance remains a serious hurdle. Drug resistance continues to be a major problem in ...

Three proteasome inhibitors (PIs) are approved for patients with multiple myeloma (MM): Bortezomib, a first-in class PI, fights both newly diagnosed and relapsed/refractory MM (RRMM); carfilzomib, a ...

BERLIN--(BUSINESS WIRE)--Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, launched today with the ...

Much like humans generate mountains of garbage, our cells are constantly discarding proteins that are damaged or no longer needed. The cellular waste disposal system called the proteasome is best ...

Although they are not alive themselves, proteins nonetheless progress through a life cycle of sorts: they are created by the cell, serve a specific purpose in the organism, and ultimately expire ...

Comprehensive detection of ctDNA variants at 0.1% allelic frequency using a broad targeted NGS panel for liquid biopsy research. Accuracy of profiling of circulating tumor DNA for CRC MRD and ...

Tyrosine kinase inhibitors to regulate the expression level of ABC transporters related to multidrug resistance. An examination of the BET bromodomain inhibitor JQ1 in comparison with histone ...

Researchers from IOCB Prague are furthering the understanding of how medicines work and what it takes to develop their most effective variants. In one current study, they have focused on the disease ...

Booster Therapeutics is ready to open up a new arm of the proteasome after raising $15 million in seed funding to advance small molecules it says can degrade multiple types of harmful proteins. Rather ...